ACVR1 and fibrodysplasia ossificans progressiva: Identifying the cells responsible for HO may facilitate development of cell-targeted therapeutic approaches for FOP, complementing ongoing drug development strategies based on inhibition of activin A8,20, ACVR1 kinase activity19 and cartilage differentiation21–23.